Precision Oncology
Personalized treatment strategies informed by tumour biology and molecular characteristics.
- Tumour biology as the starting point
- Integration of clinical, pathology and molecular information
- Treatment strategy discussed in context
Services
Four clinical groups, one integrated pathway.
Services are organised the way care actually works — diagnosis and molecular characterisation, treatment delivery, advanced therapy pathways, and research access. Each answers a clinical question, and they are most useful together.
Start here
Three main entry points.
If you are not sure which individual service applies, begin with the section closest to your situation.
Cancer Care
Diagnosis, treatment delivery, symptom support, palliative support and survivorship.
Precision Oncology
Molecular testing, genomic profiling, report interpretation and tumour board review.
Advanced Treatments
CAR-T cell therapy, immunotherapy, targeted therapy and other systemic treatments.
Referring clinicians can use the For Clinicians section for referral and molecular review pathways.
Group 01
Cancer Care & Treatment
The main patient-facing care pathway: specialist consultation, treatment delivery, care at home and independent review.
Oncology Day Care Centre
Safe, comfortable, and efficient administration of cancer treatments in a dedicated day care environment.
Services
- Chemotherapy
- Immunotherapy
- Targeted therapy
- Supportive oncology care
- Infusion monitoring
Features
- Experienced oncology nurses
- Treatment monitoring
- Emergency preparedness
- Patient counselling
Home Cancer Care
Bringing supportive oncology services closer to patients through personalized home-based care.
Services
- Home nursing
- Injection administration
- Symptom monitoring
- Palliative care support
- Follow-up care
- Sample collection
Cancer Second Opinion
Independent review of diagnosis, pathology, imaging, molecular findings and treatment history.
- Remote or in-person review
- Records reviewed before discussion
- Clarity on available options
Group 02
Molecular Oncology & Diagnostics
Molecular oncology and precision medicine services: the diagnostics and interpretation that describe the biology of an individual cancer.
Molecular Testing & Comprehensive Genomic Profiling
Genomic and molecular evaluation — including comprehensive genomic profiling — to identify potentially actionable alterations and biomarkers.
- Tissue genomic testing and NGS
- Comprehensive genomic profiling
- Biomarker and molecular pathology review
- Report interpretation in clinical context
Liquid Biopsy
Blood-based molecular testing, including circulating tumour DNA where clinically appropriate.
- ctDNA where clinically appropriate
- Useful when tissue is limited
- Considered alongside, not instead of, tissue biopsy
Molecular Tumor Board
Multidisciplinary interpretation of complex molecular findings.
- Case-based multidisciplinary discussion
- Clinical, pathology, imaging and genomic data together
- Structured interpretation of complex reports
Group 03
Advanced Therapies
Specialised treatment pathways that require dedicated eligibility assessment, coordination and protocol-specific monitoring. This group will expand as further advanced therapies — including bispecific antibodies, antibody-drug conjugates, other cellular therapies and advanced immunotherapies — are established.
CAR-T Cell Therapy
Advanced cellular immunotherapy assessment, treatment coordination and specialist monitoring for appropriately selected patients with eligible hematologic malignancies.
Services
- CAR-T therapy evaluation
- Multidisciplinary eligibility assessment
- Treatment-history review
- Leukapheresis coordination
- Cell collection coordination
- Manufacturing and logistics coordination
- Bridging-therapy planning when clinically indicated
- Lymphodepleting chemotherapy planning
- CAR-T cell infusion coordination
- Post-infusion monitoring
- Cytokine release syndrome surveillance
- Neurotoxicity surveillance
- Infection monitoring
- Supportive care
- Long-term hematology-oncology follow-up
Features
- Specialist hematology-oncology assessment
- Protocol-based eligibility screening
- Organ-function assessment
- Infectious-disease screening
- Disease-burden assessment
- Treatment-readiness review
- Chain-of-identity awareness
- CAR-T product traceability
- Toxicity escalation protocols
- Caregiver education
- Long-term monitoring planning
- Coordination with authorized CAR-T / cellular-therapy centres where required
Advanced therapies require dedicated eligibility assessment and, in some cases, coordination with an authorized cellular-therapy centre. They are not routine day-care treatments, and suitability is decided only through specialist assessment.
Group 04
Research & Access
Translational research and structured routes to investigational approaches for appropriately selected patients.
Cancer Research
Translational research focused on advancing personalized cancer care.
- Tumour genomics and biomarkers
- Liquid biopsy and molecular monitoring
- Translational and digital oncology
Clinical Trials
Clinical trials may provide access to investigational approaches for appropriately selected patients. Eligibility is strict and participation is never assumed.
- Structured review of trial relevance
- Filtering by cancer type, alteration and phase
- Discussed alongside standard treatment options
How it fits together
One pathway, with branches where treatment differs.
Most patients follow the same early sequence. What differs is the treatment route that follows.
- 01Consultation
- 02Diagnosis & pathology review
- 03Molecular testing when indicated
- 04Multidisciplinary interpretation
- 05Personalized treatment plan
- 06Treatment
Oncology Day Care
Chemotherapy, immunotherapy and targeted therapy delivered in day care.
Advanced / CAR-T Therapy
Specialist eligibility assessment and coordinated cellular therapy pathways where appropriate.
Clinical Trial
Investigational approaches for appropriately selected patients, where a trial is relevant.
Then: Follow-up & Home Cancer Care
A separate program, not a cancer service
Precision Longevity Program
by Dr AV Institute
A physician-led prevention and healthy-ageing program covering cancer risk, cardiometabolic health, genetics and family risk, nutrition, fitness, bone health, sleep and cancer survivorship. It runs alongside the oncology services above rather than forming part of them.
Explore Precision LongevityQuestions
Questions people ask about these services
Most people begin with a consultation. The clinical picture, existing pathology and imaging are reviewed first, and only then is it decided whether molecular profiling, liquid biopsy or a molecular tumor board discussion would add anything useful.
No. Existing reports are usually the starting point, and reviewing them often avoids unnecessary repeat testing. Any further testing is discussed with you before it is arranged.
Yes. Pathology, imaging, molecular reports and treatment history can be reviewed in advance and discussed remotely. Some situations still require an in-person assessment.
Testing may be performed through accredited partner laboratories. The institute's role is to decide whether a test is likely to help, and to interpret the report in the context of your clinical situation.
It depends on how complete the records are and whether further testing is needed. The team confirms an expected timeline once your records have been received and checked.
No. Molecular information can reduce uncertainty and sometimes opens options that would not otherwise be considered, but it cannot guarantee an actionable finding, a targeted therapy or a particular response.
Not sure which service applies to your situation?
A consultation can help clarify what is worth doing, and what is not.